Radiotherapy for prostate cancer is commonly used clinically for the treatment of patients with locally advanced disease. The prognosis is better with a five-year survival rate of up to 80% when radiotherapy is combined with endocrine therapy. The outcome of radiotherapy is also related to the Gleason score, i.e. the degree of prostate cancer cell deterioration. If the score is 2-6, the five-year survival rate can be 70%-80%. If the score is >8, the prognosis is poor, with a five-year survival rate of about 50%. A score of 8-10 has a five-year survival rate of about 20-30%. Local radiotherapy for prostate cancer is more effective. If the cancer is more aggressive, it is often accompanied by cancer metastasis or other risks.